Notice of Closed Meeting, 102148-102149 [2024-29645]
Download as PDF
<![CDATA[
102148
Federal Register / Vol. 89, No. 242 / Tuesday, December 17, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Clinical Laboratory
Improvement Advisory Committee
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), within the
Department of Health and Human
Services (HHS), is seeking nominations
for membership on the Clinical
Laboratory Improvement Advisory
Committee (CLIAC). CLIAC, consisting
of up to 20 members including the
Chair, represents a diverse membership
across laboratory specialties,
professional roles (laboratory
management, technical specialists,
physicians, nurses), and practice
settings (academic, clinical, public
health), and includes a consumer
representative.
SUMMARY:
Nominations for membership on
CLIAC must be received no later than
July 1, 2025. Packages received after this
time will not be considered for the
current membership cycle.
ADDRESSES: All nominations should be
emailed to CLIAC@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Heather Stang, M.S., Senior Advisor for
Clinical Laboratories, Division of
Laboratory Systems, Office of
Laboratory Systems and Response,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop H24–2, Atlanta, Georgia
30329–4027. Telephone: (404) 498–
2769; Email: HStang@cdc.gov.
SUPPLEMENTARY INFORMATION:
Nominations are sought for individuals
who have the expertise and
qualifications necessary to contribute to
the accomplishment of the objectives of
the Clinical Laboratory Improvement
Advisory Committee (CLIAC). Nominees
will be selected based on expertise in
the fields of microbiology (including
bacteriology, mycobacteriology,
mycology, parasitology, and virology),
immunology (including
histocompatibility), chemistry,
hematology, pathology (including
histopathology and cytology), or genetic
testing (including cytogenetics); from
representatives in the fields of medical
technology, bioinformatics, public
ddrumheller on DSK120RN23PROD with NOTICES1
DATES:
VerDate Sep<11>2014
19:45 Dec 16, 2024
Jkt 265001
health, and clinical practice; and from
consumer representatives. Selection of
members is based on candidates’
qualifications to contribute to the
accomplishment of CLIAC objectives
(https://www.cdc.gov/cliac/php/about/
index.html). Members may be invited to
serve up to four-year terms.
Department of Health and Human
Services (HHS) policy stipulates that
committee membership be balanced in
terms of points of view represented and
the committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on Federal workgroups or
prior experience serving on a Federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. Committee
members are Special Government
Employees, requiring the filing of
financial disclosure reports at the
beginning of and annually during their
terms. The Centers for Disease Control
and Prevention (CDC) reviews potential
candidates for CLIAC membership each
year and provides a slate of nominees
for consideration to the Secretary of
HHS for final selection. HHS notifies
selected candidates of their
appointment near the start of the term
in July or as soon as the HHS selection
process is completed. Note that the need
for different expertise varies from year
to year and a candidate who is not
selected in one year may be
reconsidered in a subsequent year.
Candidates should submit the
following items:
• Current curriculum vitae, including
complete contact information
(telephone numbers, mailing address,
email address).
• At least one letter of
recommendation from person(s) not
employed by HHS. Candidates may
submit letter(s) from current HHS
employees if they wish, but at least one
letter must be submitted by a person not
employed by an HHS agency (e.g., CDC,
National Institutes of Health, Food and
Drug Administration).
Nominations may be submitted by the
candidate or by the person/organization
recommending the candidate.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–29646 Filed 12–16–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
In accordance with 5 U.S.C. 1009(d),
the Centers for Disease Control and
Prevention (CDC) announces the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463.
Name of Committee: Safety and
Occupational Health Study Section
(SOHSS), National Institute for
Occupational Safety and Health
(NIOSH).
Dates: February 4–5, 2025.
Times: 11 a.m.–5 p.m., EST.
Place: Teleconference.
Agenda: The meeting will convene to
address matters related to the conduct of
Study Section business and for the
Study Section to consider safety and
occupational health-related grant
applications.
For Further Information Contact:
Michael Goldcamp, Ph.D., Scientific
Review Officer, Office of Extramural
Programs, National Institute for
Occupational Safety and Health, Centers
for Disease Control and Prevention,
1095 Willowdale Road, Morgantown,
West Virginia 26505. Telephone: (304)
285–5951; Email: MGoldcamp@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
E:\FR\FM\17DEN1.SGM
17DEN1
Federal Register / Vol. 89, No. 242 / Tuesday, December 17, 2024 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–29645 Filed 12–16–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–10765]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
February 18, 2025.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:45 Dec 16, 2024
Jkt 265001
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: Room C4–26–05, 7500
Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10765 Review Choice
Demonstration for Inpatient
Rehabilitation Facility (IRF) Services
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
U.S.C. 1395b–1(a)(1)(J)) authorizes the
Secretary to ‘‘develop or demonstrate
improved methods for the investigation
and prosecution of fraud in the
provision of care or services under the
health programs established by the
Social Security Act (the Act).’’ Pursuant
to this authority, the CMS will continue
the implementation of a Medicare
demonstration project, which CMS
believes will help assist in developing
improved procedures for the
identification, investigation, and
prosecution of Medicare fraud occurring
among IRFs providing services to
Medicare beneficiaries.
This demonstration will assist in
developing improved procedures for the
identification, investigation, and
prosecution of potential Medicare fraud.
The demonstration will ensure that
payments for IRF services are
appropriate through either pre-claim or
postpayment review, thereby working
towards the prevention and
identification of potential fraud, waste,
and abuse, as well as protecting the
Medicare Trust Funds from improper
payments while reducing Medicare
appeals. CMS plans to continue the
demonstration in Alabama and
Pennsylvania, then expand to Texas,
and California. After the initial four
states, CMS will expand the
demonstration to include the IRFs in
any state that bill to Medicare
Administrative Contractor (MAC)
jurisdictions JJ, JL, JH, and JE. Form
Number: CMS–10765 (OMB Control
Number: 0938–1420); Frequency:
Occasionally; Affected Public: Private
Sector (Business or other for-profits and
Not-for-profits); Number of
Respondents: 526; Number of
Responses: 179,910; Total Annual
Hours: 89,955. (For questions regarding
this collection contact Jaclyn Gray (410)
786–3744.)
William N. Parham, III
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–29638 Filed 12–16–24; 8:45 am]
BILLING CODE 4120–01–P
Information Collections
1. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Review Choice
Demonstration for Inpatient
Rehabilitation Facility (IRF) Services;
Use: Section 402(a)(1)(J) of the Social
Security Amendments of 1967 (42
PO 00000
Frm 00046
Fmt 4703
Sfmt 9990
102149
E:\FR\FM\17DEN1.SGM
17DEN1
]]>Agencies
[Federal Register Volume 89, Number 242 (Tuesday, December 17, 2024)]
[Notices]
[Pages 102148-102149]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-29645]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
In accordance with 5 U.S.C. 1009(d), the Centers for Disease
Control and Prevention (CDC) announces the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Office of
Strategic Business Initiatives, Office of the Chief Operating Officer,
CDC, pursuant to Public Law 92-463.
Name of Committee: Safety and Occupational Health Study Section
(SOHSS), National Institute for Occupational Safety and Health (NIOSH).
Dates: February 4-5, 2025.
Times: 11 a.m.-5 p.m., EST.
Place: Teleconference.
Agenda: The meeting will convene to address matters related to the
conduct of Study Section business and for the Study Section to consider
safety and occupational health-related grant applications.
For Further Information Contact: Michael Goldcamp, Ph.D.,
Scientific Review Officer, Office of Extramural Programs, National
Institute for Occupational Safety and Health, Centers for Disease
Control and Prevention, 1095 Willowdale Road, Morgantown, West Virginia
26505. Telephone: (304) 285-5951; Email: [email protected].
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
[[Page 102149]]
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-29645 Filed 12-16-24; 8:45 am]
BILLING CODE 4163-18-P
